Verified Nov 2026
Other
·
Bedford, Massachusetts
·
Since 2006
Ocular Therapeutix, Inc. is a publicly traded biopharmaceutical company headquartered in Bedford, Massachusetts, founded in 2006 and listed under the ticker OCUL. It employs between 200 and 500 people and develops and commercializes therapies for eye diseases using its bioresorbable hydrogel platform, ELUTYX. Its FDA-approved products include DEXTENZA, an intracanalicular insert for post-surgical ocular inflammation and allergic conjunctivitis. The company serves ophthalmology and healthcare markets.
Ocular Therapeutix, Inc. at a glance
Revenue
51.8M
Employees
200-500
Founded
2006
Headquarters
Bedford, Massachusetts
Ownership
Publicly traded (NASDAQ: OCUL)
Industries
Automotive
Electric Vehicles
Medical
Industrial Equipment
Overview
Ocular Therapeutix, Inc. is a publicly traded biopharmaceutical company headquartered in Bedford, Massachusetts, founded in 2006 and listed under the ticker OCUL. It employs between 200 and 500 people and develops and commercializes therapies for eye diseases using its bioresorbable hydrogel platform, ELUTYX. Its FDA-approved products include DEXTENZA, an intracanalicular insert for post-surgical ocular inflammation and allergic conjunctivitis. The company serves ophthalmology and healthcare markets.
At a glance
Attribute | Detail |
|---|---|
Founded | 2006 |
Headquarters | Bedford, Massachusetts |
Employees | 200-500 |
Revenue | 51.8M |
Ownership | Publicly traded (NASDAQ: OCUL) |
What Ocular Therapeutix, Inc. makes
Its ELUTYX hydrogel platform supports sustained drug delivery, and its approved products include DEXTENZA and ReSure Sealant, with pipeline candidates in glaucoma, wet age-related macular degeneration, and dry eye disease.
Latest developments
2026-11-02 — Ocular Therapeutix™ to Report Third Quarter 2026 Financial (globenewswire.com)
2026-09-15 — Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with (globenewswire.com)
2026-06-17 — Ocular Therapeutix™ Investor Day to Highlight U.S. FDA ... (yahoo.com)
2026-04-29 — Ocular Therapeutix™ Announces First Patient Enrolled in (globenewswire.com)
2026-01-21 — Ocular Therapeutix™ Appoints David W. Robinson as Global (globenewswire.com)
2025-11-24 — Ocular Therapeutix™ Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI™ in NPDR (globenewswire.com)
Company details
Ocular Therapeutix collaborates with Regeneron Pharmaceuticals on extended-release eye therapies. Ocular Therapeutix, Inc. was founded in 2006, has an estimated 200-500 employees, and is headquartered in Bedford, Massachusetts.
Frequently asked questions
What does Ocular Therapeutix, Inc. do?
Ocular Therapeutix, Inc. is a publicly traded biopharmaceutical company headquartered in Bedford, Massachusetts, founded in 2006 and listed under the ticker OCUL. It employs between 200 and 500 people and develops and commercializes therapies for eye diseases using its bioresorbable hydrogel platform, ELUTYX. Its FDA-approved products include DEXTENZA, an intracanalicular insert for post-surgical ocular inflammation and allergic conjunctivitis. The company serves ophthalmology and healthcare markets.
Where is Ocular Therapeutix, Inc. headquartered?
Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts (15 Crosby Drive, Bedford, Massachusetts, 01730).
When was Ocular Therapeutix, Inc. founded?
Ocular Therapeutix, Inc. was founded in 2006.
How big is Ocular Therapeutix, Inc.?
Ocular Therapeutix, Inc. has an estimated 200-500 employees, with revenue in the 51.8M range.
Is Ocular Therapeutix, Inc. publicly traded?
Publicly traded (NASDAQ: OCUL). Public financial figures are drawn from its filings.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile comes from a public-data sample of around 1,000 companies. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.